Form 425 - Prospectuses and communications, business combinations:
SEC Accession No. 0000950135-00-004493
Filing Date
2000-10-03
Accepted
2000-10-03 00:00:00
Documents
1

Document Format Files

Seq Description Document Type Size
1 ANTIGENICS, INC. FOR AQUILA BIOPHARMACEUTICALS b3667042e425.txt 425 20801
  Complete submission text file 0000950135-00-004493.txt   23454
Mailing Address 175 CROSSING BOULEVARD FRAMINGHAM MA 01702
Business Address 175 CROSSING BLVD BIOTECHNOLOGY RESEARCH PARK FRAMINGHAM MA 01702 5087975777
AQUILA BIOPHARMACEUTICALS INC (Subject) CIK: 0000704292 (see all company filings)

EIN.: 043307818 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 425 | Act: 34 | File No.: 000-12081 | Film No.: 734389
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 630 FIFTH AVENUE SUITE 2170 NEW YORK NY 10111
Business Address 630 FIFTH AVENUE SUITE 2170 NEW YORK NY 10111 2123324774
ANTIGENICS INC /DE/ (Filed by) CIK: 0001098972 (see all company filings)

EIN.: 061562417 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)